Pdt Partners, LLC Relmada Therapeutics, Inc. Transaction History

Pdt Partners, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.1 - $6.8 $4,051 - $8,887	1,307 Added 8.76%	16,227 $75,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $41,716 - $63,751	-16,821 Reduced 52.99%	14,920 $44,000
Q2 2023 Aug 14, 2023	SELL	$2.22 - $3.54 $83,518 - $133,178	-37,621 Reduced 54.24%	31,741 $78,000
Q1 2023 May 15, 2023	BUY	$2.24 - $4.76 $155,370 - $330,163	69,362 New	69,362 $156,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.